All In Biotech

Drug Trial Radar · NCT05083260

NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's Disease (PD) Participants Treated With Carbidopa/Levodopa and NE3107

Last checked: Nov 19, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Jan 4, 2022

Primary completion

Nov 21, 2022

Study completion Jan 4, 2023

Sponsor

Lead sponsor
BioVie Inc.Industry
Sponsor type
Industry
First posted
Oct 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 28-day phase 2a, double-blind, placebo-controlled (1:1), multi-center study of 20 mg NE3107, twice daily of safety, potential drug-drug interactions, and MDS-UPDRS defined activity in patients with Parkinson's disease . Study will enroll 40 patients that are currently taking immediate release levodopa/ carbidopa (IRLC) and have a practically defined early morning off-state for IRLC. Day one- baseline UPDRS and IRLC PK sampling; day 2- start NE3107 dosing, assess UPDRS during onset and NE3107 PK sampling, rescue meds as needed after 4 hours; day 3 and 14- NE3107 + IRLC UPDRS assessment and PK sampling; day 28- NE3107 + IRLC UPDRS assessments. Optional overnight stays in clinic prior to Day 1-3, 14, and 28.

Conditions

  • Parkinson Disease

Interventions

  • NE3107Drug

    NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease

  • placeboDrug

    Hard gelatin capsule containing only common excipients for oral formulations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline (day 1) in Motor disease society- Unified Parkinson's disease rating scale Part III total score for the patient in the "off-state" (without L-dopa for previous eight hours)Time frame: measured on day 1, 2, 3, 14, and 28
  2. Change from baseline in the length of time during which L-dopa therapy is ineffective in reducing motor symptoms of disease (OFF time)Time frame: off time will be measured/recorded every day from day 2 to day 27
  3. Change from baseline in average Motor disease society- Unified Parkinson's disease rating scale Part III total score measured over the course of 8 hours after taking L-dopa and/or NE3107Time frame: measured on day 1, 2, 3, 14, and 28
  4. Motor disease society- Unified Parkinson's disease rating scale Part I total scoreTime frame: measured on day 1, 2, 3, 14, and 28
  5. Motor disease society- Unified Parkinson's disease rating scale Part 2 total scoreTime frame: measured on day 1, 2, 3, 14, and 28
  6. Change from baseline in the length of time during which L-dopa-like effects are felt by the patientTime frame: baseline and day 1, 2, 3, 14, and 28
  7. change from baseline in L-dopa induced dyskinesia measured with the abnormal involuntary movement scale (AIMS)Time frame: AIMS will be measured during the 8 hour period of observation on Day 1, 2, 3, 14, and 28
  8. change from baseline in time to onset of L-dopa-like activityTime frame: measured on Day 1, 2, 3, 14, and 28
  9. Change from baseline in Non-Motor Symptom Assessment Scale for Parkinson Disease (NMSS)Time frame: Measured on Day 1, 2, 3, 14, and 28
  10. change in area under the levodopa plasma concentration vs. time curve when administered alone compared to being co-administered with NE3107Time frame: Blood samples will be collected on Day 1, 2, 3, and 14
  11. Change in the maximum plasma concentration (Cmax) of levodopa when administered alone compared to being co-administered with NE3107.Time frame: Blood samples will be collected on Day 1, 2, 3, and 14
  12. The area under the NE3107 plasma concentration vs. time curve when administered alone compared to being co-administered withTime frame: Blood samples will be collected on Day 2, 3, and 14
  13. Change in the maximum plasma concentration (Cmax) of NE3107 when administered alone compared to being co-administered with L-dopaTime frame: Blood samples will be collected on Day 2, 3, and 14

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Rocky Mountain Movement Disorders Center

    Englewood, Colorado

  • Parkinson's Disease & Movement Disorders Center Of Boca Raton

    Boca Raton, Florida

  • Velocity

    Hallandale, Florida

  • Charter Research

    Lady Lake, Florida

  • Premier Clinical Research Institute

    Miami, Florida

  • First Excellent Research Group

    Miami, Florida

  • First Excellent Research

    Miami, Florida

  • EZY Medical Research

    Miami, Florida

  • Charter Research

    Winter Park, Florida

  • Quest Research Institute

    Farmington Hills, Michigan

  • New York Neurology Associates

    New York, New York

  • Duke University

    Durham, North Carolina

  • M3 Wake Research

    Raleigh, North Carolina

  • University of Toledo

    Toledo, Ohio

  • Texas Institute for Neurological Disorders

    Sherman, Texas

  • Inland Northwest Research

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.